University at Buffalo - The State University of New York
Skip to Content

Faculty and Staff Directory

Joseph                         Paladino

Joseph A. Paladino PharmD

Department of Pharmacy Practice

Clinical Professor, Director, Clinical Outcomes & PharmacoEconomics

 
Professional Summary:

Fellowship Director, Pharmacoeconomics.

Research interest areas:

1. Pharmacoeconomic evaluation of antimicrobial therapy for pneumonia and geriatric therapy.

2. Clinical trails of developmental antibacterial agents.

Education and Training:
  • PharmD, Medical University of South Carolina (1982)
  • BS, Massachusetts College of Pharmacy (1977)
  • BS, Siena College (1975)
Employment:
  • Antimicrobial Stewardship Pharmacist (2010-present)
  • Clinical Professor (2003-present)
  • Director, Clinical Outcomes and Pharmacoeconomics Research (2001-present)
  • Antimicrobial Stewardship Pharmacist (2010)
  • Clinical Professor (2003)
  • Clinical Associate Professor of Pharmacy (1993–2003)
  • Adjunct Assistant Professor of Nursing (1989–2002)
  • Director, Clinical Outcomes and Pharmacoeconomics Research (2001)
  • Director, Pharmacoeconomic (1990–2000)
  • Director, Suburban Hospital Division (1987–2000)
  • Clinical Associate Professor of Pharmacy (1993)
  • Clinical Assistant Professor of Pharmacy (1990–1993)
  • Clinical Assistant Professor of Pharmacy (1990)
  • Director, Pharmacoeconomic (1990)
  • Adjunct Assistant Professor of Nursing (1989)
  • Director, Suburban Hospital Division (1987)
  • Adjunct Medical Staff Clinical Pharmacologist in Medicine and Pediatrics (1986–1987)
  • Clinical Instructor in Pediatrics (1985–1987)
  • Assistant Director of Pharmacy for Clinical and Educational Services (1982–1987)
  • Adjunct Medical Staff Clinical Pharmacologist in Medicine and Pediatrics (1986)
  • Clinical Instructor in Pediatrics (1985)
  • Assistant Director of Pharmacy for Clinical and Educational Services (1982)
  • Decentralized Pharmacist (1980–1982)
  • Decentralized Pharmacist (1980)
  • Chief Pharmacist (Acting) (1979–1980)
  • Community Pharmacist (1978–1980)
  • Chief Pharmacist (Acting) (1979)
  • Staff Clinical Pharmacist (1978–1979)
  • Community Pharmacist (1978)
  • Staff Clinical Pharmacist (1978)
See all (20 more)
Awards and Honors:
  • Phi Lambda Sigma, Beta Omicron Chapter. (2007)
  • Excellence in Research Award (1998)
  • Who's Who in Medicine and Healthcare (1998)
  • Who's Who in the World (1998)
  • Fellow, (1996)
  • Who's Who in Science and Engineering (1994)
  • Who's Who in America (1994)
  • Visiting Professor of Clinical Pharmacy (1992)
  • Sandoz Award for Superior Academic Achievement (1982)


Journal Articles:
  • Paladino JA, Jacobs DM, Shields RK, Taylor J, Bader J, Adelman MH, Wilton GJ, Crane JK, Schentag JJ. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2014; 44(6).
  • Paladino JA; Poretz DE. Outpatient parenteral antimicrobial therapy today.. Clinical Infectious Diseases. 2010; 51.
  • Brown J; Paladino JA. Impact of Rapid MRSA PCR Testing on Mortality and Cost-Effectiveness in Hospitalized Patients with Bacteremia: A Decision Model. Pharmacoeconomics. 2010.
  • Monte SV; Schentag JJ; Paladino JA. Characterization of Cardiovascular Outcomes in a Type 2 Diabetes Glucose Supply and Insulin Demand Model.. Journal of Diabetes Science and Technology. 2010; 4.
  • Monte SV; Schentag JJ; Paladino JA. Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents. Journal of Diabetes Science and Technology. 2010; 4.
  • Brown J; Paladino JA. Impact of rapid methicillin resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteremia: A decision model.. PharmacoEconomics. 2010; 28.
  • Prescott WA; Doloresco F; Brown J; Paladino JA. Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review.. PharmacoEconomics. 2010; 28.
  • Monte SV; Slazak EM; Albanese NP; Adelman M; Rao G; Paladino JA. Clinical and Economic Impact of a Diabetes Clinical Pharmacy Service Program in a University and Primary Care-Based Collaboration Model. J Am Pharm Assoc. 2009; 49.
  • File T; Monte SV; Schentag JJ; Paladino JA; Klugman K; Lavin B; Yu V; Singer M; Adelman M. Progression Between Chronic Obstructive Pulmonary Disease Exacerbations and Community-Acquired Pneumonia.. The International Journal of Antimicrobial Agents. 2009; 33.
  • Monte SV; Slazak EM; Albanese NP; Adelman M; Rao G; Paladino JA. Clinical and Economic Impact of a Diabetes Clinical Pharmacy Service Program in a University and Primary Care-Based Collaboration Model. Journal of the American Pharmacists Association. 2009; 49.
  • Monte SV; Prescott WA; Johnson KK; Lori K; Paladino JA. Safety of Ceftriaxone at the Extremes of Age Expert Opinion on Drug Safety. 2008; 7.
  • Paladino JA; Sunderlin JE; Singer ME; Adelman MH; Schentag JJ. Am J Health Syst Pharm. 2008; 65.
  • Paladino JA. of extended-spectrum beta-lactams on gram-negative bacterial resistance. Am J Health Syst Pharm. 2008; 65.
  • Gilliland-Johnson KK; Adelman MH; Cohn SM; Paladino JA. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections. Surg Infect (Larchmt). 2008; 9.
  • Monte SV; Albanese NP; Slazak EM; Schentag JJ; Paladino JA. Costs of treating lower respiratory tract infections. American Journal of Managed Care. 2008; 14.
  • Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA. Costs of treating lower respiratory tract infections. Am J Manag Care. 2008; 14.
  • Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA. Costs of treating lower respiratory tract infections.. Am J Manag Care. 2008; 14.
  • McKinnon PS; Paladino JA; Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008; 31.
  • McKinnon PS; Paladino JA; Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.. Int J Antimicrob Agents. 2008; 31.
  • Paladino JA; Schentag JJ. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis. 2008; 46.
  • Iannini PB; Paladino JA; Lavin B; Singer ME; Schentag JJ. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother.. 2007; 19.
  • Paladino JA; Sunderlin JL; Adelman MH; Singer ME; Schentag JJ. Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm. 2007; 64.
  • Paladino JA; Sunderlin JL; Adelman MH; Singer ME; Schentag JJ. Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm.. Observations on vancomycin use in U.S. hospitals. 2007; 64.
  • Paladino JA; Eubanks DA; Adelman MH; Schentag JJ. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc. 2007; 55.
  • Paladino JA; Adelman MH; Schentag JJ; Iannini PB. Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US.. Pharmacoeconomics. 2007; 25.
  • Paladino JA; Adelman MH; Schentag JJ; Iannini PB. Direct costs in patients hospitalized with community-acquired pneumonia after non response to outpatient treatment with macrolide antibacterials in the US. PharmacoEconomics. 2007; 25.
  • Birmingham MC, Hassett JM, Schentag JJ, Paladino JA. Assessing antibacterial pharmacoeconomics in the intensive care unit.. Pharmacoeconomics. 1997; 12(6).
See all (17 more)
Abstracts:
  • Monte SV; Podkulski L; Prescott GM; Brown J; Paladino JA; Schentag JJ; Footer B. . Impact of area-under-the-inhibitory-curve on clinical and microbiologic outcomes in fluconazole treated candidaemia. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April, 2010. 2011.
  • Monte SV; Podkulski L; Prescott GM; Brown J; Paladino JA; Schentag JJ; Footer B. A characterization of mean inhibitory concentrations and patient outcomes in patients failing to respond to fluconazole treatment of severe infections caused by Candida spp. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April, 2010. 2011.
  • Brown J; Paladino JA; Schentag JJ; Footer B. A characterization of mean inhibitory concentrations and patient outcomes in patients failing to respond to fluconazole treatment of severe infections caused by Candida spp.. European Congress on Clinical Microbiology and Infectious Dieases. 2010.
  • Brown J; Paladino JA; Schentag JJ; Footer B. Impact of area-under-the-inhibitory-curve on clinical and microbiologic outcomes in fluconazole treated candidaemia. European Congress on Clinical Microbiology and Infectious Dieases. 2010.
  • Monte SV; Adelman MH; File T; Edusei G; Paladino JA; Schentag JJ. 2009.
  • Herges J; Monte SV; Slazak EM; Albanese NP; Paladino JA. Comparison of Pharmacist-Physician Collaborative and Physician Only Management of Type 2 Diabetes Mellitus in the Primary Care Setting. ASHP Midyear Clinical Meeting. 2008.
  • File T; Monte SV; Schentag JJ; Paladino JA; Lavin B; Yu V; Singer M; Adelman M. RTI Response in the Community; Observations on the Transition State Between COPD and CAP. IDSA. 2008.
  • Monte SV; Paladino JA; Schentag JJ; Adelman M. Abstract: Clinical and economic impact of AUC24/MIC on the progression to hospitalization in COPD complicated by AECB, making a difference in infection diseases. MAD-ID. 2008.
  • Mac Evoy MS; Slazak EM; Paladino JA; Monte SV. Evaluation of atorvastatin to simvastatin conversion in a primary care physician group and the impact on quality of care. ASHP Midyear Clinical Meeting. 2007.
  • Paladino JA; Monte SV; Albanese NP; Slazak EM; Schentag JJ. Costs of Outpatients Lower Respiratory Tract Infection in an Adult Managed Care Population. ICAAC. 2007.
  • Monte SV; Paolini N; Slazak EM; Paladino JA. Cost of Outpatient Lower Respiratory Tract Infection in an Adult Primary Care Population. ASHP Midyear Clinical Meeting. 2006.
See all (1 more)

Professional Memberships:
  • New York State Department of Health; Chair, Medicaid Drug Utilization Review Committee (2009)
  • Society of Infectious Diseases Pharmacists; Elections Committee (2008)
  • Making a Difference in Infectious Diseases Pharmacotherapy; Scientific Committee (1999)
  • International Society for Pharmacoeconomics and Outcomes Research (1997)
  • Infectious Diseases Society of America (1990)
  • American Society for Microbiology (1988)
  • American College of Clinical Pharmacy (1987)
Presentations:
  • "Use of Ceftaroline after Glycopeptide Failed to Eradicate MRSA Bacteremia with High Vancomycin MICs" ICAAC, ASM (2013)
  • "Initial stages in the development of an antimicrobial stewardship program in a teaching hospital." ACCP Annual Meeting, ACCP (2011)
  • "Impact of Self-Monitoring of Blood Glucose on Cardiovascular Outcomes in Patients with Type 2 Diabetes" ASHP Midyear Clinical Meeting, ASHP (2009)
  • "Comparison of Pharmacist-Physician Collaborative and Physician Only Management of Type 2 Diabetes Mellitus in the Primary Care Setting" ASHP Midyear Clinical Meeting, ASHP (2008)
  • "Evaluation of atorvastatin to simvastatin conversion in a primary care physician group and the impact on quality of care" ASHP Midyear Clinical Meeting, ASHP (2007)
  • "Cost of Treating Lower Respiratory Tract Infection in Outpatients" 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC (2007)
  • "Cost of Outpatient Lower Respiratory Tract Infection in an Adult Primary Care Population" ASHP Midyear Clinical Meeting, ASHP (2006)
  • "Analysis of Montelukast Plus Short-acting Beta-2-agonist Versus Short-acting Beta-2-agonist Alone in a Pediatric Asthma Population" ASHP Midyear Conference, American Society of Health-System Pharmacists (2005)
Service Activities:
  • Search Committee for Vice-Chair; Review packets, discuss, and vote on a recommended individual A new Vice Chair was appointed, based on the Committee's recommendation.; Member (2013)
  • Search Committee, Vice Chair Dept Pharmacy; Prescreen and interview candidates Completed screening, planning interviews; Member (2012)
  • Admissions Committee; Interview candidates. Review e-submissions. Receomended accept or reject of numerous candidates.; Reviewer (2012)
  • Promotions Committee; Review dossiers of faculty up for promotion Receoomended promotion of two faculty; one is done, the other pending. Recommended delaying application to one faculty member, delay accepted. Conducted sereval mid-term evaluations. Discussed other faculty; Member (2012)
  • Center for HOPE; participate in decisions we became active!; Member (2011)
  • Search Committee; Prescreen and interview candidates for cHOPE faculty postions Success in hiring several PharmDs; Member (2011)
  • Search Committee; Interview candidates for Health Outcomes Fellowship Successfully filled the positions; Member (2011)
  • Board of Directors; MAD-ID Develop educational programs on infectious diseases 14th Annual Meeting held in May in Orlando, FL with >300 participants; Other (2010)
  • Support Group; East Coast Prosthetics Meet with fellow amputees to support each other; Other (2009)
  • Board of Directors; SIDP Society of Infectious Diseases Pharmacists Liaison with 3 committees, Vote on all activities of the Society developed several initiatives; Other (2009)
  • Drug Utlization Review Committee; NYS Department of Health, Medicaid Meet quarterly to discuss various programs and initiatives of the Board First Chairman (2008-2010) OF newly reconstituted board; Member (2008)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

213 Kapoor Hall
Buffalo, NY 14214-8033
Email: paladino@buffalo.edu


Log in to Update Your Profile
"); pageTracker._trackPageview();